|Year : 2020 | Volume
| Issue : 1 | Page : 5-11
A survey of practices to diagnose, manage, prevent and control COVID-19 from 28 centres
Sanjay Bhattacharya1, Ranganathan Iyer2, Kavita Raja3, Vinitha Mary Joy1, Swapna R Bijulal4, Kalpana George5, Gaurav Goel1, Shabina Santosh6, Anitha Madhavan7, M Ardra8, Debabrata Dash9, Seema Oommen10, Geethu Joe11, Anup Kumar Shetty12, Yogesh Kumar Gupta13, MS Prabhakar14, Dagny Hari Vengilat15, J Beena Philomina5, SR Sujatha16, Sasmita Hotta17, Chhavi Gandhi18, Rakesh Sehgal19, S Kirupa20, Sangeetha Sampath21, Dhruv K Mamtora22, M Kalyani23, Mallikarjun Koppad24, J Ashish25, M Santhi26, Samitha Nair27, Kuntal Kumar Sinha28, TR Neetha29
1 Department of Microbiology, Tata Medical Centre, Kolkata, West Bengal, India
2 Department of Microbiology, Global Hospital, Hyderabad, Telangana, India
3 Department of Microbiology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, Kerala, India
4 Department of Microbiology, Regional Cancer Centre, Thiruvananthapuram, Kerala, India
5 Department of Microbiology, Government Medical College, Kollam, Kerala, India
6 Department of Microbiology, Government Medical College, Kozhikode, Kerala, India
7 Department of Microbiology, Government Tirumala Devaswam Medical College, Alappuzha, Kerala, India
8 Department of Microbiology, Jubilee Mission, Thrissur, Kerala, India
9 Department of Microbiology, Bhima Bhoi Medical College and Hospital, Balangir, Odisha, India
10 Department of Microbiology, Burjeel Medical City, Abu Dhabi, UAE
11 Department of Microbiology, Deenanath Mangeshkar Hospital, Pune, Maharashtra, India
12 Department of Microbiology, Father Muller Medical College, Mangalore, Karnataka, India
13 Department of Microbiology, Fortis Escorts Hospital, Jaipur, Rajasthan, India
14 Department of Microbiology, Government Medical College, Anantapur, Andhra Pradesh, India
15 Department of Microbiology, Government Medical College, Thrissur, Kerala, India
16 Department of Microbiology, JSS Hospital, Mysore, Karnataka, India
17 Department of Microbiology, Maharaja Krishna Chandra Gajapati Medical College and Hospital, Berhampur, Odisha, India
18 Department of Microbiology, People Tree Hospitals, Bengaluru, Karnataka, India
19 Department of Parasitology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
20 Department of Microbiology, Prashanth Super Specialty Hospital, Chennai, Tamil Nadu, India
21 Department of Microbiology, Rajarajeswari Medical College and Hospital, Bengaluru, Karnataka, India
22 Department of Microbiology, SL Raheja Hospital, Mumbai, Maharashtra, India
23 Department of Microbiology, Saveetha Medical College, Kanchipuram, Tamil Nadu, India
24 Department of Microbiology, Shimoga Institute of Medical Sciences, Shimoga, Karnataka, India
25 Department of Microbiology, Sree Gokulam Medical College and Research Foundation, Thiruvananthapuram, Kerala, India
26 Department of Microbiology, Sri Ramachandra Medical College and Research Institute, Chennai, Tamil Nadu, India
27 Department of Microbiology, DDRCSRL Diagnostics Private Limited and SUT Hospital, Thiruvananthapuram, Kerala, India
28 Department of Microbiology, ABVIMS and Dr. Ram Manohar Lohia Hospital, Delhi, India
29 Department of Microbiology, AIIMS, Jodhpur, Rajasthan, India
|Date of Submission||11-Jul-2020|
|Date of Decision||13-Jul-2020|
|Date of Acceptance||27-Jul-2020|
|Date of Web Publication||13-Aug-2020|
Dr. Sanjay Bhattacharya
Department of Microbiology, Tata Medical Centre, Kolkata, West Bengal
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Bhattacharya S, Iyer R, Raja K, Joy VM, Bijulal SR, George K, Goel G, Santosh S, Madhavan A, Ardra M, Dash D, Oommen S, Joe G, Shetty AK, Gupta YK, Prabhakar M S, Vengilat DH, Philomina J B, Sujatha S R, Hotta S, Gandhi C, Sehgal R, Kirupa S, Sampath S, Mamtora DK, Kalyani M, Koppad M, Ashish J, Santhi M, Nair S, Sinha KK, Neetha T R. A survey of practices to diagnose, manage, prevent and control COVID-19 from 28 centres. J Acad Clin Microbiol 2020;22:5-11
|How to cite this URL:|
Bhattacharya S, Iyer R, Raja K, Joy VM, Bijulal SR, George K, Goel G, Santosh S, Madhavan A, Ardra M, Dash D, Oommen S, Joe G, Shetty AK, Gupta YK, Prabhakar M S, Vengilat DH, Philomina J B, Sujatha S R, Hotta S, Gandhi C, Sehgal R, Kirupa S, Sampath S, Mamtora DK, Kalyani M, Koppad M, Ashish J, Santhi M, Nair S, Sinha KK, Neetha T R. A survey of practices to diagnose, manage, prevent and control COVID-19 from 28 centres. J Acad Clin Microbiol [serial online] 2020 [cited 2021 Jan 28];22:5-11. Available from: https://www.jacmjournal.org/text.asp?2020/22/1/5/291892
| Introduction|| |
Coronavirus disease (COVID) caused by SARS-CoV-2 has emerged as a major public health problem in India as well globally., Many authoritative guidelines and practice recommendations have been published. Despite the presence of multiple guidelines and government advisories, the actual situation or ground reality with regard to policies and practices are not well known. Understanding the real situation at COVID-testing centres and COVID-treating hospitals would give a much-needed insight and may help re-calibration of recommendations and make them more implementable. The objective of this article is to survey the actual practices regarding diagnosis, treatment and prevention of COVID in various healthcare facilities within India.
| Materials and Methods|| |
The survey was conducted in the months of May and June 2020 through an online questionnaire using Google Forms software which provided opportunities to participate in the survey and provide answers. The survey link was emailed to the microbiologists within the organisation, 'The Academy of Clinical Microbiologists', as well as microbiologists outside this organisation. The questions for the survey were selected by a panel of clinical microbiologists representing the editorial board of the Journal of Academy of Clinical Microbiologists. The answers to this survey were collated in an Excel format and duplicate answers, if any, from the same centre was excluded. If there were conflicting answers given by two respondents from the same centre, telephonic conversation was held to clarify ambiguities.
| Results|| |
Types of healthcare facilities and labs
Altogether, 28 centres responded to the survey (27 from India and one from Abu Dhabi) [Figure 1]. This included 12/28 (42.86%) from the public sector (government institutions). Central government institutes were 4/28 (14.29%) of the total respondents and 8/28 (28.57%) were from state government medical colleges. Out of 16 private labs, 8 were from medical colleges. The total number of labs participating in the survey from medical college hospitals was 16/28 (57.14%). Eleven out of 28 healthcare facilities (39.29%) had a bed strength >1000; nine out of 28 (32.14%) had bed strength ranging from 200 to 500 beds, whereas, four centres each had bed strength between 0–200 and 500–1000 (14.29%). Ten laboratories out of the 28 (35.71%) had accreditation from the National Accreditation Board for Testing and Calibration Laboratories (NABL) for real-time polymerase chain reaction (RT-PCR) tests on RNA viruses. Out of these ten labs, only three were from the government sector. It was noted that in seven labs out of 28 (25.00%), efforts were on to get NABL accreditation for RT-PCR tests. In total, 17/28 (60.71%) centres were designated as COVID hospitals, out of which eight were from the government sector. Two hospitals were in the process of being designated COVID hospitals. Seven out of the 17 (41.18%) designated COVID hospitals had NABL accreditation for RT-PCR tests. Dedicated COVID unit(s) were present in 25 out of 28 centres (89.29%); among them 15/25 were from the private sector.
Laboratory testing practices
The survey revealed that COVID RT-PCR was being done in 18/28 labs (64.29%). This included 11 labs from public sector and 7 from private sector. Fifty per cent (9/18) of the labs performing the COVID tests had NABL accreditation. Seventeen out of the 18 (94.44%) healthcare facilities had designated COVID units within their organisation. It was noted that COVID-specific antibody tests were not currently done at any of the centres (0/28), however, five centres were in the process of initiating it. Out of the five, two of the centres responded that they planned to start using chemiluminescence/electro-chemiluminescence-based antibody testing systems (Architect Abbott Laboratories, Chicago; Ortho Clinical Diagnostics, USA; Roche, Switzerland). Cartridge-based nucleic acid amplification test (CBNAAT) for COVID was being done at 6/28 centres (21.43%), with two of them using Cepheid platform, while one mentioned the QIAsymphony 22 respiratory pathogen panel test. The survey showed that conventional PCR was being done at 19/28 centres (67.86%), with a combination of both manual and automated methods being used in 12/19 labs (63.16%); only automation was being used in 5/19 labs (26.32%) and manual method only in 2/19 labs (10.53%). Six of the 19 labs specified the RT-PCR platforms being used, namely Mylab kits at two centres, with others being ALTONA, TRUPCR, SEEGENE. Outsourcing of COVID tests was being carried out by 10/28 labs (35.71%), with two labs sending the samples out only for confirming with reference labs. Twenty-six centres out of 28 (92.86%) used an assay (either from their own lab or from an outsourced lab) that targeted the E gene by RT-PCR, with 21/28 (75.00%) centres using RDRP gene and nine centres using an assay for S gene detection (9/28 or 32.14%). All the three gene targets (E, RDRP and S) were used for detection by 8/28 labs (28.57%), with 19/28 using E and RDRP gene (67.86%) and 8/28 using E & S gene (28.57%). Other gene targets in SARS-CoV-2 used in detection included N2 in 4/28 (14.29% of labs) and ORF1 in 1/28 labs (3.57%).
Pre-treatment screening was done at 20/28 centres (71.43%), with 12 centres using RT-PCR and five centres using CBNAAT for COVID screening. All symptomatic staff were being tested for COVID-19 irrespective of history at 8/28 centres (28.57%), with selective testing of staff based on a local policy at 18/28 centres (64.29%). COVID-19 was being tested in only severe acute respiratory illness (SARI) cases at 5 out of 28 centres (17.86%), with 9/28 centres (32.14%) testing in SARI and influenza-like illness (ILI) cases, 2/28 centres (7.14%) in SARI and healthcare-associated infection (HCAI) cases and SARI, ILI and HCAI cases all being tested by 12/28 centres (42.86%). The survey noted that hydroxychloroquine (HCQ) was used at 10/28 centres (35.71%). HCQ prophylaxis was used at 8/28 centres (28.57%), empirical HCQ treatment at 6/28 centres (21.43%), whereas use of HCQ for targeted therapy only in lab-confirmed cases of COVID at 10/28 centres (35.71%). Other anti-COVID drugs were being used at 15/28 centres (53.57%), with Azithromycin at 10/28 centres (35.71%) and Lopinavir-Ritonavir at 13/28 centres (46.43%). Two centres out of the 28 (7.14%) had started plasma therapy for the management of some of their COVID patients. Remdesivir was used in critically ill patients admitted to intensive care unit at only one centre.
Infection prevention and control practices
COVID test for asymptomatic contacts was done at 24/28 centres (85.71%), with majority (13/24) tested on day five and day 14 (54.17%); four centres (16.67%) tested only on day 14 and 7/24 (29.17%) centres tested only on day five after exposure. Patient isolation rooms were available at 22/28 centres (78.57%), with 12/28 (42.86%) having neutral pressure isolation rooms and 10/28 (35.71%) having negative-pressure isolation rooms [Figure 2]. Designated isolation rooms for sample collection were available at 24/28 centres (85.71%). Personal protective equipment (PPE) was available at all centres although it was in limited supply at two centres. PPEs for eye protective (either goggles or face shield) was available in all labs, gowns were available at 26/28 centres (92.86%) and full body PPE including cap and shoe cover were available at only one centre.
|Figure 2: Availability of isolation rooms in the participating hospitals|
Click here to view
| Discussion|| |
A survey of diagnostic, therapeutic and infection prevention and control practices within the country is an essential component of learning, capacity building and review of policies protocols. This article aims to have a collective understanding about COVID-related processes and procedures within India so that individual and institutional practitioners may benefit from the survey report.
A study from the Indian Council of Medical Research in the early days of the COVID pandemic reported that: 'Within a week of standardization of the test at National Institute of Virology, Pune, all Viral Research Diagnostic Laboratories could initiate testing for SARS-CoV-2'. The ICMR report also described that the quarantined individuals were tested twice – at days zero and 14., In this study, we have not explored the question of capacity of individual labs with regard to maximum numbers that they could process per day by various RT-PCR platforms, but the geographical spread of the respondents suggest that COVID testing capability had expanded to various parts of the country.
Surveys to review diagnostic practices in epidemic or pandemic situations are not new. Lee et al. in 2016 in connection with the Middle Eastern respiratory syndrome-associated coronavirus (MERS-CoV) reported from South Korea that most of the specimens sent for diagnosis by RT-PCR were sputum (73.5%). The median turnaround time (TAT) was 5.29 h in the 26 medical institutions covered in the survey. RT-PCR-based techniques can be performed within a working day shift of eight h. This includes two–three h for RNA extraction, about thirty to sixty min for PCR set-up and two–three h for PCR and post-PCR analysis. CBNAAT systems are much faster and can deliver the results in about one hour. To reduce TAT, the following steps may be considered apart from CBNAAT technology: automation of RNA extraction, automation of PCR set up systems (e.g., automated liquid handling systems such as Qiagility, PCR equipment with faster ramp rate; kits with faster PCR cycle parameters, automation of post-PCR analysis and reporting using laboratory information system).
It was reported that during the MERS pandemic many laboratories were able to perform tests throughout the whole week. This is important from a public health point of view but requires reorganisation of human resources. Laboratory biosafety preparedness in MERS-CoV and SARS-CoV included Biosafety Level- 2 laboratories with class II biosafety cabinets. Generally, a separated pre-PCR, PCR, MasterMix preparation rooms are required for conventional real-time PCR systems; however, these requirements are changing because of CBNAAT technology. Like MERS CoV, SARS CoV-2 requires ideally a negative pressure sample pre-treatment room for RNA extraction and ideally a negative pressure sputum/nose-throat swab sample collection room.
Surveys on diagnostic practices in COVID also reveal interesting facts. A Canadian study reported that there was a wide variety of PCR instruments, reagents, PCR targets and reaction conditions used between the different diagnostic and commercial RT-PCR methods for the identification of SARS-CoV-2. Despite this variability, the limit of detection or analytical sensitivity of the PCR assay of the various laboratory-developed tests (LDTs) or home brew assays were between 3.4 and 4.5 log10 copies/mL (2511–31,622 copies/mL). Most commercial assays surveyed were equivalent to the home brew assays. This shows that with good quality control, it is possible for individual labs or reference labs with good molecular biology expertise to develop reliable diagnostic assays.
Similarly, a European consortium representing 87 labs from 23 countries reported that 45% of the surveyed labs had a test in place by 26 March, which is well into the first wave of the pandemic in most countries. Positive and negative controls (specificity panels) are essential for the development of home brew assays (LDTs). The European survey reported that the main implementation barriers for introduction of a SARS-CoV-2 molecular assay in European diagnostic laboratories were non-availability of positive controls and a specificity panel. Our study revealed that more labs use imported kits than made-in-India kits. This reflects an urgent need to develop indigenous technology and make adequate provisions for seamless transfer of technology to the manufacturing companies. There is also a need to develop repository for quality control strains of viruses within India which are commercially available (e.g., National Institute for Biological Standards and Control, UK).
Knowledge, attitude and practice (KAP) are essential for any disease management, and COVID is not an exception. In India's neighbourhood, a study from Pakistan showed that healthcare workers had good knowledge (93%), a positive attitude (mean 8.43) and good practice (89%) regarding COVID-19. The attitude section in this study was assessed using responses to seven questions in a 5-point Likert scale (1, strongly agree; 2, agree; 3, undecided; 4, disagree; 5, strongly disagree). In addition, a study on healthcare workers in Pakistan perceived that limited infection control material and poor knowledge regarding transmission were the major barriers to infection control.
In a questionnaire-based survey, the awareness among healthcare students and professionals in Mumbai metropolitan region was assessed. It was noted that <50% of the total survey participants could correctly define 'close contact'. More than 75% of the responders were aware of the various infection control measures such as rapid triage, respiratory hygiene and cough etiquette and having a separate, well-ventilated waiting area for suspected COVID-19 patients. However, only 45% of the responders were aware of the correct sequence for the application of PPEs such as a mask/respirator, and only 53% of the responders were aware of the preferred hand hygiene method for visibly soiled hands. For any capacity-building activity, emphasis on KAP is essential. The NABL accreditation of the labs, which was the requirement by the government for private labs for permission to provide COVID PCR services, ensures that staff are recruited after a proper assessment of qualification, skills, knowledge through interview, competency assessed periodically and standard operating procedures to ensure uniformity of practice are in place. In our study, 35% of the labs had NABL accreditation.
A study from China, which covered 1070 specimens collected from 205 patients, reported virus detection from a variety of clinical specimens. In this survey, we did not elaborate on the sample types processed. Nose swab and throat swab in viral transport medium is the overwhelmingly common sample types processed. Bronchoalveolar lavage fluid specimens showed the highest positive rates (14 of 15; 93%) in this Chinese study, followed by sputum (72 of 104; 72%), nasal swabs (5 of 8; 63%), fibrobronchoscope brush biopsy (6 of 13; 46%), pharyngeal swabs (126 of 398; 32%), faeces (44 of 153; 29%) and blood (3 of 307; 1%). Interestingly, none of the 72 urine specimens tested positive for SARS-CoV-2. The mean cycle threshold (Ct) values of all specimen types were more than 30 (<2.6 × 104 copies/mL) except for nasal swabs with a mean Ct value of 24.3 (1.4 × 106 copies/mL), indicating higher viral loads in nasopharyngeal samples. Live SARS-CoV-2 was observed in the stool sample from two patients who did not have diarrhoea. The above findings are important as they show that various samples have different positivity rates and viral loads. While we deal with samples from COVID positive patients be it for other microbiology investigations (bacteriology or mycology) or for other lab investigations (haematology, chemistry and cytology), the possibility of non-respiratory samples having SARS-CoV-2 needs to be remembered and appropriate measures taken to mitigate the risk.
The evidence regarding the efficacy of HCQ in COVID has been equivocal at best and negative in recent meta-analyses. In the meta-analysis by Sarma et al. it was reported that treatment with HCQ resulted in a smaller number of cases, showing the radiological progression of lung disease. No difference was observed in virological cure or death, and safety, when compared with the control/conventional treatment. However, the meta-analysis by Singh et al. reported no benefit on viral clearance but a significant increase in mortality with HCQ-treated group compared to control in patients with COVID-19., A recent review by the Oxford Centre for evidence-based medicine concluded that as HCQ and macrolide antibiotics can prolong the QT interval in electrocardiogram, combining these treatments increases this risk and the combination should be used with extreme caution and only when the advantages outweigh the disadvantages. In our study, we found that HCQ was used as an empirical treatment at 21% of the centres and for targeted therapy at 35% of the centres. Only 28% of the centres used HCQ for prophylactic purposes. This shows that majority of the centres are not using HCQ for therapeutic reasons. This could be a reflection of the facts till date from the meta-analysis.
Remdesivir was recently issued the Emergency Use Authorization (EUA) on one May 2020, by the Food and Drug Administration for its compassionate use in critically ill COVID-19 patients. Pre-clinical studies showed significant reduction in viral load in both prophylactic and therapeutic use against SARS-CoV, making it a viable option for therapy in the future. Studies and case reports show varying response to its use, in both virological and clinical cure, although there were fewer adverse effects and better tolerability to the dosage regimen. The major bottleneck for its use to further clinical studies is the limited availability and high cost, which needs to be overcome to demonstrate its verity. In our study, only one centre reported the use of Remdesivir in critically ill patients. The loading dose of this drug which needed intravenous administration was 200 mg on day followed by 100 mg daily for a total of ten days. Liver dysfunction has been identified as one of the significant side effects of Remdesivir. The current approximate cost of Remdesivir is Rs. 60,000 for a ten-day course (approx. Rs. 5500/100 mg of 10 mL vial).
Although RT-PCR is essential for the detection of acutely infected individuals, the role of serology in COVID diagnosis is being explored. A meta-analysis by Kontou et al. which evaluated immunoglobulin M (IgM) and immunoglobulin G (IgG) antibody tests on serum samples tests based on enzyme-linked immunosorbent assay (ELISA), chemiluminescence immunoassays (CLIA), fluorescence immunoassays (FIA) and the lateral flow immunoassays (LFIA) provided important insights about the role of serological assays in the detection of exposures to SARS-CoV-2. The study looked at 38 studies from 7848 individuals. The meta-analysis concluded that the tests using the S antigen were more sensitive than N antigen-based assays. IgG serological tests performed better than IgM tests in terms of sensitivity, especially when samples were taken later (peak antibody concentration was five to twelve days for IgM and twenty days for IgG). Looking at the dynamics of IgM and IgG antibody response, it was suggested that a combined IgG/IgM test was a better choice in terms of sensitivity than measuring either antibody alone. All immune-assay methods yielded high specificity with ELISA and LFIA having close to 99% clinical specificity, justifying the choice by the two participating centres to start SARS-CoV-2 serology using these platforms. ELISA- and CLIA-based methods performed better in terms of sensitivity (90%–94%) followed by LFIA and FIA with sensitivities ranging from 80% to 89%. In our study, 17.85% of the centres were considering the possibility of the antibody tests. This is understandable in view of its availability and value in the clinical perspective. Antibody tests will not replace PCR-based tests. It will add value to diagnosis through some additional information in terms of exposure.
| Conclusion|| |
In this article, we have documented through a questionnaire-based survey the different practices in the management of COVID pandemic from 28 centres spread over 11 states/union territories of India as well as one from Abu Dhabi [Figure 1]. The major findings of the survey have included: (a) use of the conventional RT-PCR as the main system for COVID testing with cartridge-based system as the second most preferred RT-PCR system; (b) very few centres considering antibody tests for assessment of COVID infection; (c) majority of the centres not using HCQ for treatment of COVID; (d) majority of the centres not using HCQ as a chemoprophylaxis against COVID; (e) majority of the centres (about two-third) did not have a negative-pressure isolation room for managing COVID patients. We have noted variability of diagnostic practices [Table 1] and facilities for patient isolation [Figure 2]. We have also reviewed the literature pertinent to the topic. Through this exercise, we hope that clinical microbiologists, laboratory administrators and infection control specialists would get an idea about prevailing practices. We hope that this will facilitate strategic planning and capacity building. NABL accreditation to enable labs to initiate SARS-CoV-2 diagnostics earlier (either by molecular and/or serologic methods), the ability to adapt existing facilities and equipment during such epidemics and efficient collaboration between laboratory and clinical departments are essential in combating and triumphing over this 21st-century pandemic. COVID management requires strategic planning and operational efficiency at the administrative and technical level. There is a constant need to pay attention to quality control of testing processes and re-calibrate clinical and infection control policies in the light of changing clinical evidence and government advisories. This study shows that despite the diversity there is a certain degree of uniformity and standardisation of practices. It is likely that this is happening because of the close scrutiny of data by state/central government and ICMR.
|Table 1: Descriptive data from 28 individual laboratories – coronavirus disease 2019 diagnostics and management|
Click here to view
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Indian Council of Medical Research. SARS-CoV-2 (COVID-19) Testing Status. Available from: https://www.icmr.gov.in/
. [Last accessed on 2020 Jul 03].
Gupta N, Potdar V, Praharaj I, Giri S, Sapkal G, Yadav P, et al
. Laboratory preparedness for SARS-CoV-2 testing in India: Harnessing a network of Virus research diagnostic laboratories. Indian J Med Res 2020;151:216-25.
] [Full text]
Lee MK, Kim S, Kim MN, Kweon OJ, Lim YK, Ki CS, et al
. Survey of clinical laboratory practices for 2015 Middle East respiratory syndrome coronavirus outbreak in the republic of Korea. Ann Lab Med 2016;36:154-61.
LeBlanc JJ, Gubbay JB, Li Y, Needle R, Arneson SR, Marcino D, et al
. Real-time PCR-based SARS-CoV-2 detection in Canadian laboratories. J Clin Virol 2020;128:104433.
Matheeussen V, Loens K, Lammens C, Vilken T, Koopmans M, Goossens H, et al
. Preparedness of European diagnostic microbiology labs for detection of SARS-CoV-2, March 2020. J Clin Virol 2020;128:104432.
Saqlain M, Munir MM, Rehman SU, Gulzar A, Naz S, Ahmed Z, et al.
Knowledge, attitude, practice and perceived barriers among healthcare professionals regarding COVID-19: A Cross-sectional survey from Pakistan [published online ahead of print, 2020 May 8]. J Hosp Infect. 2020;105:419-23.
Modi PD, Nair G, Uppe A, Modi J, Tuppekar B, Gharpure AS, et al
. COVID-19 Awareness among healthcare students and professionals in Mumbai metropolitan region: A Questionnaire-Based Survey. Cureus 2020;12:e7514.
Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al
. Detection of SARS-CoV-2 in Different Types of Clinical Specimens [published online ahead of print, 2020 Mar 11]. JAMA. 2020;323:1843-4.
Singh AK, Singh A, Singh R, Misra A. “Hydroxychloroquine in patients with COVID-19: A Systematic Review and meta-analysis.” Diabetes Metab Syndr 2020;14:589-96.
Sarma P, Kaur H, Kumar H, Mahendru D, Avti P, Bhattacharyya A, et al
. Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis. J Med Virol 2020;92:776-85.
Venkatasubbaiah M, Dwarakanadha Reddy P, Satyanarayana SV. Literature-based review of the drugs used for the treatment of COVID-19. Curr Med Res Pract 2020;10:100-9.
Kontou PI, Braliou GG, Dimou NL, Nikolopoulos G, Bagos PG. Antibody Tests in Detecting SARS-CoV-2 Infection: A Meta-Analysis. Diagnostics (Basel). 2020;10:319.
[Figure 1], [Figure 2]